JDRF Canadian Clinical Trial Network launches new clinical trial for children and adolescents living with type 1 diabetes
OTTAWA, Nov. 3, 2011 /CNW/ - JDRF Canadian Clinical Trial Network (JDRF
CCTN) is pleased to announce the launch of the first multi-centre
pediatric study in Canada using insulin pump therapy and continuous
glucose monitoring (CGM). Based at the Children's Hospital of Eastern
Ontario (CHEO) in Ottawa and led by JDRF CCTN researcher, Dr. Margaret
Lawson, the study - Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes Trial (CGM TIME Trial) - will involve 128 children and teenagers aged five to 18 years
old with type 1 diabetes (T1D). The goal of the study is to find
better ways for youths to manage the disease and, in particular,
determine the best times to introduce CGM usage among this age group.
CGM devices provide both a real-time snapshot of the glucose levels of a
person with diabetes, as well as trend information on whether glucose
is moving upwards or downwards, and how fast. The devices also provide
warnings when the glucose is becoming too high or too low. JDRF's
landmark CGM trials have shown that CGMs can significantly improve
diabetes control and decrease the frequency of high and low blood
sugars when used regularly. However, a significant number of children
in the studies, and particularly teens and young adults, did not use
the CGM devices consistently.
"While insulin pump therapy is popular amongst children, teens and their
parents, the majority of pediatric pump users do not achieve adequate
diabetes control, which means they are still at risk of developing
diabetes-related complications in later years," said Dr. Lawson,
Pediatric Endocrinologist, CHEO. "What's more, recent studies have
shown that even testing blood glucose levels 10 times per day isn't
enough - and in the periods between testing, many children still
experience highs and lows which affect their diabetes control and their
sense of well-being. That's why the CGM TIME trial is important,
because we know CGMs can significantly help children and teens manage
their diabetes more effectively when used with insulin pumps. We just
need to determine at what point in their lives they will easily adopt
the diabetes technologies."
"More than three million Canadians live with some form of diabetes. This
number is increasing by three to five per cent every year, and the
greatest rise is in children five to nine years of age," said Andrew
McKee, President and CEO of JDRF Canada. "This study will explore how
children with type 1 diabetes, their parents and their health care team
can optimally manage their disease so that kids can have the best
quality of life while preventing the onset of complications."
The addition of CGM to pump therapy is central to the development of an
artificial pancreas system - an automated closed loop system which will
disperse insulin based on real-time changes in blood sugar levels. The
artificial pancreas would enable people living with T1D to maintain
blood sugar levels within the normal range with minimal effort,
resulting in better quality of life and lower risks of complications (www.artificialpancreasproject.com).
"The Government of Canada is proud to support this innovative diabetes
research, which will lead to treatments that will benefit patients not
only in Canada, but around the world," said the Honourable Gary
Goodyear, Minister of State for the Federal Economic Development Agency
for Southern Ontario (FedDev Ontario). "Clinical trials, like Dr.
Lawson's at CHEO, are creating new jobs and keeping Southern Ontario at
the forefront of world-class research and commercialization
The study is being led by CHEO with participation from four other
Ontario pediatric diabetes centres: Markham Stouffville Hospital, the
Children's Hospital at London Health Sciences Centre, The Hospital for
Sick Children (SickKids) and McMaster Children's Hospital.
JDRF is the worldwide leader for research to cure T1D. It sets the
global agenda for diabetes research, and is the largest charitable
funder and advocate of diabetes science worldwide.
The mission of JDRF is to find a cure for diabetes and its complications
through the support of research. T1D is an autoimmune disease that
strikes children and adults suddenly, and can be fatal. Until a cure is
found, people with T1D have to test their blood sugar and give
themselves insulin injections multiple times or use a pump - each day,
every day of their lives. And even with that intensive care, insulin is
not a cure for diabetes, nor does it prevent its potential
complications, which may include kidney failure, blindness, heart
disease, stroke, and amputation.
Since its founding in 1970 by parents of children with T1D, JDRF has
awarded more than $1.5 billion to diabetes research, including $107
million last year. More than 80 per cent of JDRF's expenditures
directly support research and research-related education. For more
information, please visit www.jdrf.ca.
About JDRF CCTN
Created in partnership with the Government of Canada, funding for JDRF
CCTN came from a commitment of $20 million by FedDev Ontario, with an
additional $13.9 million contribution from JDRF. The $33.9 million
investment will help accelerate the testing of new technologies and
treatments for Canadians and individuals around the world living with
T1D and its complications.
JDRF CCTN is a groundbreaking effort to accelerate solutions for the
management, care and cure of T1D. JDRF CCTN is currently developing
several high-profile clinical trials, in association with leading
diabetes researchers at partner universities and medical centers in
Southern Ontario. The goal is to position Southern Ontario as an
international hub for diabetes translational research, innovation, and
commercialization of new therapeutics and enabling technologies. For
more information, please visit www.jdrf.ca/cctn.
SOURCE Juvenile Diabetes Research Foundation
For further information: